<DOC>
	<DOCNO>NCT02964429</DOCNO>
	<brief_summary>The main purpose study determination in-vivo ultrafiltration coefficient ( in-vivo KUF ) Diacap Pro dialyzer follow routine dialysis prescription United States .</brief_summary>
	<brief_title>Determination In-vivo KUF Diacap Pro Hemodialyser</brief_title>
	<detailed_description>The in-vivo KUF Diacap Pro High Flux dialysers surface size 1.3/ 1.6/ 1.9 sqm determine require US guideline `` Guidance Content Premarket Notifications Conventional High Permeability Hemodialyzers 1998 '' comparison in-vitro KUF data . Clinical data least 12 patient collect determination in-vivo KUF complement safety- , performance-data removal small middle molecular substance hemocompatibility data .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Written inform consent obtain patient parents/ guardian . 2 . Subject age &gt; 18 3 . Effective blood flow 350 ml/min dialysate flow range 500 800 ml/min 4 . On hemodialysis minimum 3 month 5 . Use Cimino Goretex shunt 6 . Routine dialysistreatment 240 min 3 time per week 7 . Documented dialysis adequacy parameter spKt/V &gt; =1.2 stable past 3 month 8 . Plan dialyze participate hemodialysis center least 3months duration . 9 . Free currently know unusual clot access problem 10 . Hepatitis B surface antigen ( HbsAg ) negative , document within past 90 day Hepatitis B surface antibody ( antiHBs ) positive . 11 . Anti HCV negative , document within past 90 day 12 . Anti HIV negative , document within past 90 day Hematocrit ( HCT ) 25 40 % haemoglobin ( Hb ) less 8 g/dL 1 . Patients unable tolerate effective blood flow 350 ml/min 2 . Patients use catheter dialysis 3 . Pregnant nursing woman . Women childbearing potential must agree avoid pregnancy study period 4 . Previous plan extend absence participate hemodialysis centre 5 . Expected transplanted ( live relate donor ) within maximum 3 month study period 6 . Any serious medical condition disability , opinion investigator , would interfere treatment assessment preclude completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>